Pacific Biosciences Of California | PACB - Cash And Equivalent

Pacific Biosciences Of California reported $325.09M in Cash and Equivalent for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Cash And Equivalent Change
Accelerate Diagnostics AXDX:US USD 38.99M 34.41M
Agilent A:US USD 1.25B 197M
Bruker BRKR:US USD 645.5M 19.3M
Danaher DHR:US USD 6B 845M
Fluidigm FLDM:US USD 81.31M 21.11M
General Electric GE:US USD 17.26B 4.67B
Illumina ILMN:US USD 2.01B 1.01B
Myriad Genetics MYGN:US USD 3.3M 49.6M
Nanostring Technologies NSTG:US USD 112.25M 4.82M
Pacific Biosciences Of California PACB:US USD 325.09M 20.66M
Perkinelmer PKI:US USD 454.36M 53.62M
Quidel QDEL:US USD 292.9M 80.7M
Roche Holding ROG:VX 4.99B 676M
Thermo Fisher Scientific TMO:US USD 8.52B 5.6B
Waters WAT:US USD 481.39M 37.75M